Team
Our team unites deep scientific, clinical and business expertise to bring life-saving tissue therapeutics into the clinic backed, by 100 years of tissue engineering experience.
Management
Alexander Leutner
CO-CEO (Business) & Co-founder
Formerly founded, scaled & successfully exited deep-tech start-up to Hexagon. 12 years building and leading teams in start-up and corporate settings.
Dr. Simon MacKenzie
CO-CEO (Therapeutic Programs)
Former CEO at RegenHU; CBO at Axol Bioscience; Director at Kyorin Pharmaceutical Co. 25 years leading biotech & pharma therapeutics teams across US, EU, Asia.
Dr. Kathy Kordy, MD
Chief Medical Officer
Former Head of Rare Disease &. Immunology, Johnson&Johnson; Exec. Dirrector., Pediatric Drug Dev., Novartis; Pediatric gastro-hepatologist & clinical pharmacologist., UCLA & CHLA. 20 years experience in medical & drug dev., driving innovative therapies to new markets.
Dr. Tobias Lam
CTO & Co-founder
Creator of Cellbricks‘ bioprinting technology. 10 years experience of 3D-bioprinting, biomaterial
formulation and 3D-Bioprinter development.
Michael Kring
CFO
Owner of High Tech Corporate Services, former Group CFO at BioNTech SE. 20 years experience in financial modelling and controlling.
Troy Dale
Chairman of the board
Former Head of Strategic Partnerships Unit, Novartis; Former Chief Marketing Officer Greater China, Sanofi. 30 years experience as pharmaceutical executive. History of strategic conceptualisation through to ‚on the ground‘ execution of strategy.
Therapeutic Program Leads
Alexander Thomas
Soft Tissue Program Lead & Co-founder
PhD on bioprinted vasculature. 10 years experience of 3D-bioprinting, tissue engineering and building vasculature.
Dr. Alicia Ruppelt
Liver Tissue Program Lead
Former R&D liver engineer at Life Tec Group; Researcher at Merck. 6 years experience of 3D-bioprinting & tissue
engineering – scientific & managerial industry expertise.
